HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
NCT04396626 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 975
Last updated 2023-04-27
Summary
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-18
- Primary Completion
- 2020-05-31
- Completion
- 2020-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
NCT06040593 ·Status: COMPLETED
-
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
NCT01548677 ·Status: COMPLETED ·Phase: PHASE2
-
Biology Guided Therapy for Breast Cancer for ER Positive
NCT04965688 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01275677 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer
NCT06639672 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
NCT07342309 ·Status: ACTIVE_NOT_RECRUITING
-
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
NCT04419181 ·Status: WITHDRAWN ·Phase: PHASE2
-
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
NCT01329627 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
NCT04857619 ·Status: COMPLETED
-
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
NCT00003440 ·Status: COMPLETED ·Phase: PHASE3
-
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
NCT02560311 ·Status: UNKNOWN
-
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.
NCT06126003 ·Status: TERMINATED
-
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
NCT06033287 ·Status: RECRUITING
-
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755 ·Status: RECRUITING
-
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
NCT06276868 ·Status: RECRUITING ·Phase: PHASE2
-
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
NCT04753177 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
NCT00134680 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
NCT01152606 ·Status: COMPLETED
-
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
NCT06207734 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
NCT06791161 ·Status: ENROLLING_BY_INVITATION